Member Info for BBB11

Mornington, interested, what other boards?

Does anyone else think the buys today are extremely odd. It looks like every single share sold is being bought immediately, no matter the value. There have been several large sales, all bought back immediately.

Anyone else think this could be an institution buying with intent. Promising for shareholders regardless.

Monday RNS… yes please! To the moon

What are the next milestones over the next 6 months, which will count as good news? Outside of funding, what do we think are the next big SP risers?

First patient injected?

CBR update?

US Military funding grant from Dec conference?

It is generally true, but you have instances where it is not, e.g, Prevail. So it is likely you’re right, but it is a not a cold hard fact it would be at a discount. We already have a ridiculously low SP, and you have raise history to take into account. Previous investors are more likely to secure the investment at a similar price, not for a discount on the cost, but to secure their investment at a critical stage.

I had a look, that is correct, with shareholders approval it can be extended significantly.

Even AstraZenica was part of one for Daiichi Sankyo Partnership,

Very true. Unfortunately they don’t, neither do other businesses right now, funding is hard for everyone as interest rates are so high. Why not invest that 4m at a guaranteed government bond at 4.5% or risk it for a 6%/7% return?

You’re correct in this, it was 2p, i checked the wrong dates. Mobile not computer right now

Just looked, day before RNS on the 2p fundraise at £4m it was 1.5p average for the week.

I believe the max is 20% per annum. I could be wrong though as i am a retail investor. Seems unlikely though… my calculation was 166m, so not sure where 69m came from quoted below.

The cost is they run our of money and the company goes to 0p and we all lose our investment; so i dont think there is an alternative if non dilutive funding is not available.

You understand that by going private that they would have to find a PE or VC firm to buy ALL IPO shares on the market ? So by your logic, instead of a 4m raise, they need to raise £18-£22m (depending on the cost of using an investment bank) for make that change.

How is it possible for Prevail to dilute it at 5.6p? They get interested parties; negotiate, go with the best offer. Pharma rarely raises anything at the daily SP as it is so volatile.

My personal opinion after spending my weekend researching every part of this stock and the pre/clinical market.

Hemo is unlikely to secure non-dilutive funding at this stage, as most companies only manage that after Phase 1 results, which for CAR-T typically take 12-18 months. If they manage to secure it earlier, it would be exceptional, with a more realistic timeframe being winter 2025 or early 2026.

They can issue up to 20% of their total shares annually, which means they still have around 166 million shares left to issue. While dilution is a concern, the key will be the price at which these shares are placed. A higher price, like the 5.6p Prevail paid, would minimize dilution compared to a lower price like their previous 2p placements, and could even increase the share price if investors like Prevail continue to hold their shares, signaling confidence in the company.

One major concern right now is the mass sell-offs of the stock, like today, which have driven the share price down significantly. This is largely due to no funding announcement being made yet, leading to uncertainty. This exact scenario has happened three times since I’ve been invested, and it’s shaken investor confidence. The last funding round in 2024, after the FDA lifted the hold on HEMO-CAR-T, saw a spike to 6.30p, but the price fell to 1.18p by August, driven by slow trial progress and a lack of communication.

Despite the dilution risk, announcing funding—dilutive or not— will help calm the SP and provide some stability by addressing the current cash flow concerns. People are selling because Vlad always announces or obtains funding late, and investors don’t want to risk their money in that scenario.

For many long-term holders (LTHs), this investment is more than just financial. Many are either cancer sufferers or family members of AML/ALL patients, invested in the hope of seeing these treatments succeed. We’re all in this together, hoping for a breakthrough.

My personal opinion is that dilution funding is likely, with a $3-4m raise, probably at 2p. This may be followed by a government grant from the US military for viral infections, and then by late 2025, a partnership or acquisition by a large pharma company once data has been released.

Should move us positive, especially with a non dilutive funding announcement at 7am tomorrow, or Monday… here is to hoping Hemogenyx are one of the first to do it at this stage of development.

Hargreaves L showing it as 7% up already. Hopefully, we stay up today.

The latest RNS from Hemogenyx shows Prevail Partners investing $350,000 at a 275% premium to the current share price. While the financial amount might seem small, it’s an obvious strategic move with a few clear motivations:

1. Confidence in Hemogenyx's CAR-T Program: Prevail is signalling strong confidence in Hemogenyx's potential, particularly with their upcoming pediatric CAR-T trials targeting AML and ALL. Paying a premium shows they believe the market is undervaluing the company's long-term share price and they want to be involved in this latest update, with the new trial on children in particular.

2. Strategic Alignment: With Prevail InfoWorks acting as the CRO for the trial, this investment aligns their operational success with Hemo’s. Their investment isn't just financial; it's about ensuring the trial's success.

3. Small, Targeted Investment: The $350k is likely covering the early trial costs for the childrens study, and we could see more funding as other milestones are hit. It’s also worth noting that the financial amount of this minimizes dilution for shareholders—always a positive!

Overall, this premium investment is a huge vote of confidence and a sign that Hemogenyx is on the right track. A lot to be excited about as the clinical trials move forward, especially as this shows a clear partnership between the investor and company, but also that they see potential in this new area of pediatric research.

I have always read about shorters on here… thought it was doomsayers. but my god you can see them posting after this increase. ‘Is it enough’… no company throws away $350,000 for no reason. Theres another funding announcement imminently.

Hope all the shorters lost a lot of money and keep doing so. Last time we had a similar Wednesday RNS we were up 70% by close on the friday.

Because otherwise the company goes bust

No, they need to raise further funding. They have reduced their cost base significantly so have until end of the year, maybe February at a push if you estimate the £1.3m cash they have left, but they will need additional funding to get CAR-T to the end of stage 1 clinical trials, and lots more funding to get through stage 2 and 3. The hope is we have a non dilutive partnership arrangement which adds financial resources to complete this, giving Hemogenyx Royalties and resources to get there from a big pharma company. If we have further dilution funding this will cause pain for LTH’s without a much higher Share Price.

Typically you only get a partnership arrangement like this when you have positive results, so a lot is hanging on the balance of the data / results of the first lot of patients to receive CAR-T treatment.